Related Experiment Video
Updated: May 2, 2026

Complete and Partial Aortic Occlusion for the Treatment of Hemorrhagic Shock in Swine
Published on: August 24, 2018
Considerations in perioperative assessment of valproic acid coagulopathy
1Department of Anesthesiology, Children's National Medical Center, The George Washington University Medical Center, NW Washington, DC, USA.
Insights
Valproic acid, an antiepileptic drug, can cause bleeding problems (coagulopathy) in children. This review examines the occurrence, seriousness, and management recommendations for this VPA side effect.
Area of Science:
- Pediatric Pharmacology
- Hematology
- Drug Safety
Background:
- Valproic acid (VPA) is a common antiepileptic medication for children.
- VPA has various therapeutic indications in pediatric populations.
- VPA can lead to coagulopathy, a bleeding disorder, posing clinical challenges.
Purpose of the Study:
- To review the incidence and severity of valproic acid-induced coagulopathy in children.
- To summarize current recommendations for managing VPA-related bleeding risks.
- To highlight the clinical implications for pre-operative assessment and patient care.
Main Methods:
- Systematic review of studies on VPA and coagulopathy.
- Analysis of documented cases of VPA-induced bleeding abnormalities.
- Compilation of expert guidelines and recommendations.
Main Results:
- Valproic acid is associated with an increased risk of coagulopathy in pediatric patients.
- The severity of VPA-induced coagulopathy can vary.
- Evidence-based recommendations for management are available but require wider implementation.
Conclusions:
- VPA-induced coagulopathy is a significant adverse effect requiring careful consideration in pediatric patients.
- Pre-operative evaluation and management strategies must account for VPA therapy.
- Further research may refine management protocols for VPA-related bleeding risks.
Abstract:
Valproic acid (VPA) is one of the widely prescribed antiepileptic drugs in children with multiple indications. VPA-induced coagulopathy may occur and constitute a pharmacological and practical challenge affecting pre-operative evaluation and management of patients receiving VPA therapy. This review summarizes the different studies documenting the incidence, severity and available recommendations related to this adverse effect.
Related Concept Videos
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis IV: Nursing Management
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Esophageal Varices-II: Clinical Features and Management
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...

